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Kesan Ekstrak Metanol Terpiawai Phyllanthus niruri (Linn.) Terhadap 
Metabolisme Drug Fasa I dan II dan Penjelasan Mekanisme Molekulnya dalam 
Hati Tikus 
 
ABSTRAK 
Phyllanthus niruri (P. niruri) merupakan tumbuhan ubatan yang ditemui secara 
meluas di kawasan tropikal dan subtropical di dunia.  Di Malaysia, ia dikenali sebagai 
“Dukong Anak”.  Banyak kesan-kesan terapeutik tumbuhan ini telah dilaporkan 
termasuk antivirus khususnya terhadap  hepatitis B dan HIV (human immune deficiency 
virus), antihiperurisemia, menyingkirkan batu karang pada ginjal dan pundi hempedu, 
serta aktiviti antinosiseptif, antiradang, antihiperlipemia, antihipertensif, antiparasit dan 
antimikrob. Kajian fitokimia ke atas tumbuhan ini menunjukkan kandungan kimianya 
yang pelbagai, antaranya, lignan, alkaloid, flavonoid, sterol, koumarin, benzenoid, tanin, 
dan  triterpena.  Berdasarkan penggunaan produk  perubatan herba yang semakin 
meluas, maka kemungkinan interaksi ubat-herba telah meningkat.  Tidak banyak yang 
diketahui tentang insidens interaksi ubat-herba pada pesakit yang mengambil P. niruri 
dengan ubat lain. Kajian ini bertujuan menyelidik kesan in vitro dan ex vivo ekstrak 
metanol terpiawai daripada P. niruri pada enzim metabolisme fasa I dan II dalam hati 
tikus di bawah pengaruh penyakit  (diabetes dan hipertensi),  jantina, dan umur  serta 
untuk menjelaskan mekanisme molekul bagaimana ekstrak memberi kesan pada 
metabolisme aminopirin fasa I. Kajian in vitro mendapati bahawa ekstrak metanol 
terpiawai daripada P. niruri tidak menunjukkan kesan yang signifikan pada  
metabolisme aminopirin fasa I pada tikus-normal daripada jantina dan kumpulan umur 
yang berbeza. Sementara itu, ekstrak pada kepekatan yang tinggi (10 µg/mL) 
menunjukkan kesan induksi yang signifikan pada tikus - diabetes dan tikus-hipertensi 
spontan.   Jantina dan umur didapati mempengaruhi kesan ekstrak metanol terpiawai 
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daripada P. niruri terhadap metabolisme aminopirin fasa I di bawah keadaan penyakit 
(diabetes dan hipertensi).  Tiada kesan signifikan diperhatikan pada dos akut  (rawatan 
satu dos) dan subkronik (rawatan harian selama 14 hari) daripada ekstrak terhadap 
aktiviti aminopirin N-demetilase pada tikus-diabetes betina muda yang terpilih.  Dalam 
kajian  in vitro fasa II, tiada kesan signifikan diperhatikan terhadap aktiviti enzim  
glutation S-transferase (GST) dan UDP-glukuroniltransferase (UGT).  Walau 
bagaimanapun, kajian   ex vivo akut menunjukkan kesan induksi tidak bergantungan dos 
yang signifikan terhadap aktiviti  enzim GST pada dos  (500 mg/kg, 1000 mg/kg, 2000 
mg/kg, dan  5000 mg/kg), dan terhadap aktiviti enzim UGT  pada  dos (1000 mg/kg, 
2000 mg/kg, dan 5000 mg/kg). Kajian ex vivo menunjukkan kesan induksi bebas dos 
yang signifikan terhadap aktiviti  enzim GST pada dos 500 mg/kg dan  2000 mg/kg.  
Sementara itu, tiada kesan yang signifikan diperhatikan pada aktiviti enzim UGT dalam 
kajian  ex vivo subkronik. Suatu kemungkinan wujud bahawa interaksi yang sama boleh 
berlaku secara in vitro dan ex vivo dengan ubat lain, yang menjalani  tindak balas 
hepatik N-demetilasi fasa I  dan glutation  fasa II  dan tindak balas konjugasi 
glukuronida. Kajian seterusnya diperlukan untuk menentukan samada kesan ini juga 
dihasilkan in vivo.  Kajian mekanisme molekul mencadangkan bahawa kesan induksi 
yang dihasilkan oleh ekstrak metanol terpiawai P. niruri terhadap aktiviti  aminopirin  
N-demetilase pada tikus-diabetes betina muda, adalah kebanyakannya melalui lintasan 
cAMP-PKA. Ekstrak metanol terpiawai Phyllanthus niruri telah dipiawaikan dengan 
sebatian tulen   filantin menggunakan  HPLC-UV.  Spektra infra merah (IR) dan  lampau 
ungu    daripada ekstrak menunjukkan kesamaan kualitatif dengan juzuk juzuk utama. 
Aktiviti penghapusan DPPH dan yang tinggi diperhatikan dalam ekstrak mengesahkan 
akan kandungan fenolnya yang amat tinggi.                         
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Effect of Standardised Methanolic extract of Phyllanthus niruri (Linn.) on Phase I 
and II Drug Metabolism and its Molecular Mechanism Elucidation in Rat Liver 
ABSTRACT 
Phyllanthus niruri (P. niruri) is a widely available medicinal plant in tropical and 
subtropical regions of the world. In Malaysia, it is locally known as “Dukong Anak”. 
Many therapeutic effects of this plant have been reported including antiviral effects 
especially on hepatitis B and human immune deficiency virus (HIV), anti-
hyperuricemic, removal of kidney and gall stones, anti-nociceptive, anti-inflammatory, 
anti-hyperlipemic, anti-hypertensive, anti-parasitic and anti-microbial activities. 
Phytochemical studies of this plant showed diversity of chemical contents such as 
lignans, alkaloids, flavonoids, sterols, coumarins, benzenoids, tannins, and triterpenes. 
Due to the wide use of herbal medicinal products, the possibilities of herb-drug 
interactions have increased. Little is known about the incidence and consequences of 
herb-drug interactions in patients who consume P. niruri concomitantly with other 
drugs. The aims of this study were to investigate the in vitro and ex vivo effects of 
standardized methanolic extract of P. niruri on phase I and II metabolizing enzymes in 
rat liver under the influence of diseases (diabetes and hypertension), gender, and age, as 
well as to elucidate the molecular mechanism by which it affect aminopyrine phase I 
metabolism. The in vitro study found that standardized methanolic extract of P. niruri 
did not show significant effect on phase I aminopyrine metabolism in normal rats of 
different gender and age groups while the extract at the higher concentration (10 µg/mL) 
showed significant induction effect on diabetic rats and spontaneously hypertensive rats. 
Gender and age were found to influence the effect of standardized methanolic extract of 
P. niruri on aminopyrine phase I metabolism under disease conditions (diabetes and 
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hypertension). No significant effect were observed in acute (single dose treatment) and 
sub-chronic (daily treatment for 14 days) doses of the extract on aminopyrine N-
demethylase activity in the selected diabetic young female rats. In phase II in vitro 
study, no significant effect were observed on glutathione S-transferase (GST) and UDP-
glucuronyltransferase (UGT) enzymes activity. However, acute ex vivo study showed 
significant dose independent induction effect on GST enzyme activity at doses (500 
mg/kg, 1000 mg/kg, 2000 mg/kg, and 5000 mg/kg), and on UGT enzyme activity at 
doses (1000 mg/kg, 2000 mg/kg, and 5000 mg/kg). Sub-chronic ex vivo study showed 
significant dose independent induction effect on GST enzyme activity at doses 500 
mg/kg and 2000 mg/kg, while no significant effect was observed on UGT enzyme 
activity in the sub-chronic ex vivo study. A possibility exist that similar interactions may 
occur in vitro and ex vivo with other drugs that undergo hepatic phase I N-demethylation 
and phase II glutathione and glucuronide conjugation reactions. Whether this effect is 
similarly produced in vivo still needs further investigations.The molecular mechanism 
study suggests that the induction effect produced by the standardized methanolic extract 
of P. niruri on aminopyrine N-demethylase activity in young female diabetic rats was 
mainly through cAMP-PKA pathway. Methanolic extract of P. niruri was standardized 
with the authentic compound phyllanthin using HPLC-UV. Infrared (IR) and 
Ultraviolet/Visible spectra of the extract showed qualitative similarities with their major 
constituents. The high DPPH scavenging and anti-oxidant activity observed in the 
extract confirmed its highly phenolic contents.      
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Chapter One 
General Introduction 
 
1.1 Definition of Herbal Products 
Herbal product in general can be defined as a plant or part from plant or an extract 
from plant used as a flavor, fragrance, or for medicinal purposes (Blumenthal and Loren 
D. Israelsen, 1998) , while herbal medicinal product is defined as any medicinal product 
that contains active ingredient from herbal origin which may be from the whole plant or 
part from it to treat ailment or promote health (Silano et al., 2004). Herbal medicinal 
products may contain active ingredients from aerial or underground part of the plant and 
may be a combination of ingredients from more than one plant and these ingredients 
may be in the form of juices, essential oils, fatty oils and gums. Excipients may be added 
to the active constituents in the final product (Blumenthal and Loren D. Israelsen, 1998). 
 
1.1.2 Uses of Medicinal Herbs in The World  
It is a duty, sacred and obligatory from the beginning of life to rescue  human  from                      
clutches of  disease. Natural  products especially  from plant  origin have been used for a 
very  long  time for  treatment  of  different  types  of  illnesses; indeed during thousands  
of  years of  development, there was a considerable increase to use herbs in medicine 
(Panda, 2000). The term phytomedicine is used to describe the use of plant or its parts to 
treat ailment in an effort of human to free himself from diseases. 
       
       Babylonion clay tablets 3000 B.C. showed that human used plants for several things  
such  as  magic, ceremonies  and   medicine  (Fetrow and O'Neil, 2002). In Egypt, herbal 
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medicine is regarded as one of the oldest medicine system, which is called Ebers 
papyrus dating 1500 B.C. It contains a list of 877 herbal recipes for treatment of variety 
of illnesses (Balch and Rister, 2002). China and India are also regarded from the ancient 
recorded herbal medicine system. This is indicated by the oldest chinese pharmacopoeia 
Pen-ts'ao around 3000 B.C. and Ayurveda, which is the ancient science of natural health 
in India (Kowalchik and Hylton, 1998). 
 
The  development  of  chemical  analysis  started  in  the  early of  19th   century  and  
scientists  were  able  to  extract and  modify  the  active  ingredients  of  plants. Later  as  
science advanced, chemists discovered their own version of plant compounds. Medicinal  
herbal   products  were  synthesized   and  a  transition  from  raw  herbs to the  synthetic  
pharmaceutical products (Mauseth, 2009).  
 
The interest with herbal medicine continues and currently, about 25% of our 
medicines came from chemicals of natural origin especially herbs. Many researches in 
the 20th century continued to show the effect of medicinal plants to treat and cure variety 
of illnesses (Khalsi, 2009). World Health Organization (WHO) estimated that up to 80% 
of world population are using traditional medicine for primary health care (Akintonwa et 
al., 2009). In USA, the use of traditional medicine was increased from 33.8% in 1990 to 
42.1%  seven years later (Eisenberg et al., 1998).  In Japan, the use of herbal medicine 
increased up to 77% in 1993 compared to only 28% in 1979 (Kanba et al., 1999). In 
Australia, 50% of population are using natural products in 2000 (Braun and Cohen, 
2007). A study on a group of Chinese community in Canada showed that more than 50% 
of them are using complementary and alternative medicine (Quan et al., 2008). A study 
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on an Indian community in South Africa showed that 38.5% of them used 
complementary and alternative medicine between 2000-2001 (Singh et al., 2004). 
 
The high interest on natural medicine is due to many factors, such as, the high cost 
of new drugs, lack of treatment for many chronic diseases, increase side effects of 
synthesized medicines, and increase in their microbial resistance (Patwardhan et al., 
2005).  
 
1.2 Use of Herbal Medicine in Malaysia 
The  tropical  climate  of   Malaysia  blessed  it  with  an  abundance  of  plants  with 
economical values and many of which are therapeutically important. In terms of  number 
of   plant  species, Malaysia  is  among   the  world  12 mega  biodiversity-rich  countries  
(Ang, 2004).  
 
Complementary and alternative medicine (CAM) is widely used in Malaysia and 
other South East Asian countries for many centuries and this is indicated by the 
traditional Malay medicine which was used from about 1000 years and continued till 
now (Raden and Werner, 1985). Nowadays, it was reported that a high prevalence of 
Malaysian people are using medicinal herbs to treat various types of diseases (Aziz and 
Tey, 2009). About 1300 medicinal plant products was registered by Malaysian Ministry 
of Health and are available in the market (Lin, 2005). This highly scientific attention 
with herbal medicinal plants in Malaysia started more than 50 years ago, when these 
medicinal plants entered the laboratory-based scientific research specially  
phytochemical screening, which was then followed by isolation and structural 
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elucidation of  the active ingredients in medicinal plant (Kiang et al. 1961; Ibrahim, 
2004). 
 
Malaysia is a multi racial country; this can be seen in herbal medicinal products 
which contain Malay herbal products, Chinese herbal products, Indian herbal products 
and Western herbal products. Each racial group is using its own traditional products for 
the treatment  of  various  illnesses  depending on  their  knowledge, believe, respect and  
confidence to their traditions (Zakaria and Mohd, 1994). 
 
 Due  to  high  consumption  of  herbal  products  to  modify  or  treat   a   variety  of  
illnesses, a special concern has raised because these herbal medicines  are  not rigorously  
regulated  by the  Malaysian   Drug   Control   Authority (DCA). At the moment, this 
authority is only concerned with the evaluation of the quality and safety aspects of 
natural medicinal products, but still  its work  is  limited in this field and the problem is  
compounds  due  to the lack of a good  quality information and scientific evidence of 
these herbal medicinal products (Aziz, 2004), hence many herb-drug interactions have 
been occurred like the interaction of St. John’s wort, kava kava, ginseng and garlic with 
the anticancer drugs irinotecan and imatinib (Meijerman et al., 2006). Ginkgo, garlic and 
ginseng interact with warfarin and may cause bleeding. St. John’s wort has been found 
to inhibit the action of oral contraceptive and anticoagulant drugs (Williamson, 2003).    
 
        Burkill, (1935), and Farnsworth & Soejarto, (1991) reported a number of medicinal 
plants which are used traditionally in Malaysia with their local name, action and 
traditional use. Examples of these herbs are listed in Table 1.1.  
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Table 1.1: Some of Medicinal  Plants  Used  in  Malaysia  with  Their Local  Name,                            
                  Chemical Constituents and Traditional Use. 
 
 
 
Species (Family) 
 
Local name 
 
Chemical 
constituent (s) 
 
Traditional use 
 
Andrographis 
paniculata Nees 
(Acanthaceae) 
 
Pokok cerita, 
hempedu bumi 
 
Andrographolide, 
neoandrographolide
 
Bacillary dysentery 
 
Areca catechu L. 
(Palmae) 
 
Pokok pinang 
 
Arecoline 
 
Anthelmintic 
 
Carica papaya L. 
(Caricaceae) 
 
Betik 
 
Chymopapain 
 
Proteolytic,mucolytic
 
Centella asiatica (L.) 
(Umbelliferae) 
 
Pegaga 
 
Asiaticoside 
 
Vulnerary 
 
Dioscorea spp. 
(Dioscoreaceae) 
 
Gadung 
 
Diosgenin 
 
Contraceptive 
 
Quisqualis indica L. 
(Combretaceae) 
 
Akar dani, akar 
pontianak 
 
Quisqualic acid 
 
Anthelmintic 
 
Ricinus communis L. 
(Euphorbiaceae) 
 
Jarak 
 
Castor oil 
 
Laxative 
 
Nicotiana tabacum 
L. (Solanaceae) 
 
Tembakau 
 
Nicotine 
 
Insecticide 
 
Curcuma longa L. 
(Zingiberaceae) 
 
Kunyit 
 
Curcumin 
 
Choleretic 
 
Mentha spp. 
(Juncaceae) 
 
Pudina 
 
Menthol 
 
Rubefacient 
 
Ananas comosus (L.) 
Merr. (Bromeliaceae) 
 
Nenas 
 
Bromelain 
 
 
Anti-inflammatory, 
proteolytic agent 
 
                                                                   (Burkill, 1935; Farnsworth and Soejarto, 1991) 
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1.3  Introduction to Drug Metabolism 
Drug metabolism can be defined as the biochemical modification or degradation 
that usually occur through specialized enzymatic system to convert the lipophilic 
chemical compounds  into  more  polar products to  be  easily excreted from  the body. 
The rate of biotransformation is important to determine the duration and intensity of 
pharmacological drug action. This rate may be affected by drug absorption which 
depend on physical properties of the drug and also may be affected by intestinal 
enzymes before entering the liver (Uetrecht and Trager, 2007). 
 
Most of the organs and tissues in our body contain a diverse and various drug 
metabolizing enzymes, but liver is considered as the most important organ for drug 
metabolism. These drug metabolizing enzymes have a central role in the metabolism, 
elimination and detoxification of drugs and other xenobiotics that enter into the body. 
 
       Drug metabolism is usually divided into three phases: phase I (functionalization 
reactions), phase II (conjugation reactions) and phase III reactions for some phase II 
metabolite in order to be excreted (Xu et al., 2005). Phase I reactions, which are known 
also as functionalization reactions prepare the drug to enter phase II reactions by 
inserting a functional reactive group into the drug or other xenobiotic structure on which 
phase II enzymes will work to make the drug more water soluble to be easily excreted 
through bile or urine. Phase II enzymes  are known as conjugating enzymes and are 
regarded as the real detoxification system for drugs and other xenobiotics (Gibson and 
Skett, 1994).  
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1.3.1 Phase I Hepatic Drug Metabolism Reactions 
The main metabolic biotransformation reactions for phase I are: 
 
1.3.1.1    Oxidation Reactions 
Oxidation reactions are the most important reactions of phase I biotransformation as 
it is performed for large number of xenobiotics that enter the body. Oxidation reactions 
are mainly performed in the presence of mixed function oxidase system, which contains 
a membrane bound iron-containing cytochrome P450, NADPH-dependant reductase and 
molecular oxygen. During this reaction oxygen atom is inserted to drug molecule as a 
result of electron transfer from NADPH to the enzyme-substrate complex, thus will 
allow cytochrome P450 to oxidize the complex. 
 
       Cytochrome  P450  enzymes  are  mainly  located  in  the  microsomal  endoplasmic  
reticulum of the liver; they are heme proteins and their name was derived from its 
characteristic in spectrophotometer, as its maximum absorption spectrum is at 450nm 
(Goldfrank et al., 2002). 
 
A variety of xenobiotics including drugs that are metabolized through mixed 
function oxidase system in the microsomes are shown in Table 1.2. 
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Table 1.2: Phase I Microsomal Oxidation Reactions by Mixed Function Oxidase System          
                  with an Example of Substrate for Each Reaction. 
 
 
                   Reaction                          Substrate 
  
  i.               Epoxidation 
  ii.              Aromatic hydroxylation 
  iii.             Aliphatic hydroxylation 
  iv.             N-, S- and O-dealkylation 
 
  v.              N-oxidation 
  vi.             N-hydroxylation 
  vii.            De-amination 
  viii.           De-sulfation 
              
             Benzo[a] pyrene 
             Chlorobenzene 
             Phenobarbital, Phenytoin  
             Aminopyrine, 6-methyl thiopurine  
             and Codeine  
             3-methyl pyridine  
             2-acetyl amino fluorine 
             Amphetamine   
             Parathion     
                          
                                                                               (Deshpande, 2002; Wilson et al., 2004) 
 
Another type of oxidation reaction is known as non-microsomal oxidation reactions, 
which are performed by enzymes not related to mixed function oxidase and involved 
primarily in oxidation of endogenous compounds (Gibson and Skett, 1994; Deshpande, 
2002). The types of such oxidation reactions with an example of their substrates are 
shown in Table 1.3. 
 
Table 1.3: Types of Phase I  Non-Microsomal Oxidation Reactions with an  Example of    
                  Substrate for Each Reaction. 
 
 
                          Reaction                    Substrate 
 
i- Amine oxidation 
ii- Alcohol oxidation 
iii- Aldehyde oxidation 
iv- Purine oxidation 
v- Aromatization 
 
 
                Catecholamine, Histamine 
                Ethanol 
                Aldehyde 
                Hypoxanthine 
                Cyclohexene carboxylic acid 
                                                                        (Gibson and Skett, 1994; Deshpande, 2002) 
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1.3.1.2    Reduction Reactions 
         Reduction reaction is a reaction that is catalyzed by hepatic microsomes in the 
presence of NADPH cytochrome P450 reductase. Many endogenous compounds and 
xenobiotics are substrates for reduction reactions like carboxylic acid esters, carboxylic 
acid amide, carboxylic acid thioesters, azo compounds, nitro compounds, quinones and 
halogenated hydrocarbons (Barile, 2004). 
 
1.3.1.3    Hydrolysis Reactions 
           Hydrolysis reactions are one of the important reactions of phase I metabolism. 
Ester, amide, hydrazide and carbamate groups are the main groups that enter hydrolysis 
reactions. Examples of drugs that enters such type of reaction are acetylsalicylic acid, 
carbamazepine, indomethacin, hexobarbital and phensuximide (Gibson and Skett, 1994; 
Hernández and Rathinavelu, 2006). 
 
1.3.1.4    Hydration Reactions 
         Epoxides are the main groups that undergoes phase I hydration reactions. The 
enzyme epoxide hydrolase, which is located in the microsomal fraction is responsible for 
hydration reaction by the addition of water molecule to the compound. This reaction is 
regarded as a detoxification reaction for dihydrodiol products (Timbrell, 2002). 
 
1.3.2   Phase II Hepatic Drug Metabolism Reactions 
        Phase II or conjugation reactions involve a variety of enzymes that catalyze the 
addition of polar group to the foreign molecule like phase I metabolite. This reaction 
involves the replacement of hydrogen atom in the carboxyl, amine or hydroxyl group 
 10
with the conjugating group (Ionescu and Caira, 2005). After the addition of polar group, 
the foreign molecule become more water soluble and easily cleared from the body 
through bile or urine (Timbrell, 2002). The main phase II conjugation reactions are 
conjugation with sugar, glutathione, sulfation, methylation, acetylation, amino acid, fatty 
acid & cholesterol ester conjugation and condensation reactions (Gibson and Skett, 
1994). 
 
1.3.2.1   Conjugation with Sugar 
Glucuronidation, which is conjugation with α-D-glucuronic acid (UDP-GlcA), is the 
major route of sugar conjugation. UDP-GlcA is the reaction co-factor which is almost 
found in all body tissues as it is an intermediate in glycogen synthesis; liver is regarded 
as the major site of glucuronidation and this reaction is catalyzed by the microsomal 
enzyme UDP-glucuronyltransferase (UGT). Many endogenous compounds are 
metabolized by glucuronidation through the conjugation of glucuronic acid to various 
reactive groups like alcohols, hydroxyl amines, phenols, amines, carboxylic acids, thiols 
and sulfonamides.  
 
The glucuronides formed from glucuronidation reactions can be classified according 
to the nature of reactive group of substrate that binds with glucuronic acid to: 
 
a. O-glucuronides 
These glucuronides are formed from glucuronic acid conjugation with alcohols, 
phenols and carboxylic acids. Carboxylic acids will form acyl or ester glucuronides 
while alcohols and phenols will form ether glucuronides (Ionescu and Caira, 2005). Acyl 
 11
glucuronides formed from carboxylic acid are susceptible to nucleophilic substitution, 
acting as electrophiles which can react with thiol or hydroxyl groups of cell 
macromolecules and such interaction may be responsible for the toxicity of some 
compounds (Burchell, 1999). The ideal example of this type of glucuronidation are 
NSAIDs (Ionescu and Caira, 2005). 
 
b. N-glucuronides 
The main substrates for this type of glucuronidation reactions are carboxyl amides, 
sulfonamides and different types of amines. N-glucuronides may be formed 
spontaneously without the presence of enzyme (Gibson and Skett, 1994). 
 
c. S-glucuronides 
The main substrate of such type of glucuronidation reactions are aliphatic and 
aromatic thiols as well as dithiocarboxylic acid (Ionescu and Caira, 2005). 
 
In insects, glucose conjugation is more  prevalent than glucuronic acid  conjugation. 
Some times UDP-xylose or UDP-ribose can conjugate to the active group of some 
compounds yielding xylosides or ribosides. N-ribosides are the most common reactions 
which formed non-enzymatically and  an example  of such  reaction  is N-ribosylation of  
2-hydroxynicotinic acid (Gibson and Skett, 1994). 
 
1.3.2.2   Glutathione Conjugation 
Glutathione reduced form (GSH) is a protective compound in the body that removes 
potentially toxic electrophilic compounds. It is a tripeptide compound comprised of 
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glycine, cysteine and glutamic acid. Usually after GSH attachment to the reactive group, 
it is further metabolized to yield N-acetyl cysteine conjugate or mercapturic acid. The 
main chemical compounds that undergo glutathione conjugation reaction are epoxides, 
alkenes, nitroalkanes, haloalkanes and aromatic halo and nitro compounds. Liver is 
regarded as the main site of glutathione conjugation reactions because of its high 
concentration of GSH (Gibson and Skett, 1994; Casarett et al., 2001). 
 
Reduced glutathione (GSH) is considered to be one of the most important redox 
molecule that posses a protective antioxidant activity inside the cell, this is because of its 
high concentration inside the cell comparing with other redox molecules. It performs the 
antioxidant action via the oxidation of the thiol group in its cysteine residue to the 
disulfide (GSSG)  form (Han, 2006). Glutathione conjugation reaction is catalyzed by 
glutathione S-transferase (GST) enzyme, which is located in the cytosol of liver, kidney 
and gut. Seven sub-family classes have been recognized for cytosolic GST in mammals 
namely alpha, mu, pi, zeta, theta, omega and sigma (Frova, 2006). Different gene 
families have the same function but differ in their substrate specificities (Chin et al., 
2008). Mu and Pi GST subfamilies are the major members of GST family that are 
involved in glutathione conjugation with chemotherapeutic agents, reactive oxygen 
species and a wide range of xenobiotics (Gao et al., 2002). 
 
1.3.2.3    Sulfation 
Sulfation is an important phase II pathway of metabolism, which involves the 
transfer of inorganic sulfate to the hydroxyl group present on phenols and aliphatic 
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alcohols yielding ethereal sulfates or sulfate esters. Sulfation reactions also occur on 
aromatic amines and hydroxyl amines to form sulfamate and N-O-sulfate. Sulfation 
reactions are catalyzed by sulfotransferases, which are a group of soluble enzymes found 
in liver, kidney, lung and intestinal tract. The product of sulfation reaction is more 
soluble than the parent compound and mainly excreted through urine, although some of 
the products are degraded enzymatically. The donor of inorganic sulfate in the reaction 
is 3'-phosphoadenosine-5'-phosphosulfate (PAPS), which is synthesized from inorganic 
sulfate and ATP. Through a complex oxidation sequence, cystiene is the major source of 
inorganic sulfate to form PAPS (Deshpande, 2002). 
 
According to the kind of substrate, there are four sulfotransferases involved in 
detoxification processes: Hydroxy steroid sulfotransferase conjugates hydroxyl steroids 
and certain primary and secondary alcohols. Aryl sulfotransferase conjugate phenol, 
catecholamines and organic hydroxyl amines. Bile salt sulfotransferase catalyzes 
sulfation of bile acids. Finally estrone sulfotransferase conjugates phenolic groups on the 
aromatic ring of steroids (Spies and Gandolfi, 1986). Although sulfate conjugates 
detoxify chemicals but some sulfated products may be toxic like N-O-sulfate esters of 
N-hydroxy-2-acetyl aminofluorene, which is not stable and degrade to form potent 
electrophilic species. 
 
1.3.2.4    Methylation 
Methylation reactions are mainly involved in the metabolism of endogenous 
compounds via methyltransferase enzymes. There are three main kinds of 
methyltransferase enzymes, which are N-, S- and O-methyltransferases. S-adenosyl 
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methionine (SAM) produced from L-methionine and ATP using L-methionine adenosyl 
transferase as a catalyst is the main methyl donor in methylation reaction. In contrast to 
other phase II reactions, methylation reactions do not lead to more polar metabolites. 
Methylation is an important reaction in epinephrine and melatonin biosynthesis. It also 
play a key role in the inactivation of biogenic amines like dopamine, serotonin and 
histamine. Some drugs may be methylated by non-specific methyltransferase found in 
the lung (Hernández and Rathinavelu, 2006). 
 
1.3.2.5    Acetylation 
Acetylation reactions are common for alkyl and aromatic amines, which conjugate 
with acetic acid to form the corresponding acetyl conjugates. This reaction involves the 
transfer of acetyl group from the co-factor acetyl co-A to the drug molecule using N-
acetyl transferase enzyme as a catalyst for this reaction. Acetylation occurs mainly in the 
liver and to a less extends in the spleen, lung and gut. Acetylated metabolites are usually 
less water soluble than the parent compound unlike other most conjugation reactions, 
this is may be due to conversion of ionizable amines in to non-ionizable amides. 
Isoniazid is an example of drug under go acetylation reaction (Gibson and Skett, 1994; 
Pandit, 2006). 
 
1.3.2.6    Amino Acids Conjugation 
Amino acid conjugation is a special form of N-acetylation reaction in which a 
carboxylic acid group of xenobiotics can react with the amino group of amino acids such 
as glycine, taurine, glutamine, ornithine and arginine. This reaction involves the 
production of acyl-CoA thioester from xenobiotic interaction with CoA by acyl-CoA 
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synthase enzyme, then the enzyme N-acetyl transferase, catalyze the transfer of the acyl 
group of xenobiotic to the amino group of amino acid. The main substrates of this type 
of conjugation reaction are heteroaromatic, aromatic, aliphatic, cinnamic and aryl acetic 
acids (Manchee et al., 2004).  
 
1.3.2.7    Fatty Acids Conjugation 
An example of such type of phase II conjugation reaction is the fatty acid 
conjugation of 11-hydroxy-Δ9-tetrahydrocannabinol. The main fatty acids involved in 
this conjugation reaction are stearic and palmitic acid and this reaction are catalyzed by 
the microsomal fraction of the liver. A little information is known about the mechanism 
of such reaction and whether that other compounds are conjugated by this way (Gibson 
and Skett, 1994). 
 
1.3.2.8    Condensation Reactions 
Condensation reaction is a detoxification reaction that is mainly observed between 
amines and aldehydes. This reaction is not enzymatic but purely chemical and an 
example of such reaction is the condensation of dopamine with its own metabolite 3,4-
dihydroxyphenyl ethanal (Smith and Hotchkiss, 2001). 
 
1.4 Phase III Hepatic Drug Metabolism Reactions 
Some compounds derived from phase II conjugation reactions may undergo further 
metabolism which is known as phase III biotransformation reactions in order to be easily 
excreted. These reactions are catalyzed by enzymes which are also active in phase I & II 
(Vermeulen, 1996). It is becoming increasingly recognized that the effect of xenobiotic 
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and their metabolites on living organism is depending on their transport out of the cell 
and this transport process are now sometimes regarded as phase III metabolism (Iersel et 
al., 1999). The possible example for such type of metabolic reactions is sulphur 
containing conjugates like GSH-conjugates, which undergoes further metabolism by the 
enzyme cysteine conjugate β-lyase (C-S lyase) (Smith and Hotchkiss, 2001). 
 
1.5 Drug Interaction 
A drug interaction is a situation in which the activity of a drug is affected by another 
substance administered together with it; such effect may be induction or inhibition or 
appearance of a new effect neither produced on its own. The interaction may be with 
another drug (drug-drug interaction), or interaction with food (drug-food interaction) as 
well as with herb (drug-herb interaction) (Griffin and D’arcy, 1997). 
 
The relation between drug administration and response can be explained by two 
phases, which are pharmacokinetic phase and pharmacodynamic phase. Pharmacokinetic 
phase is concerned with drug administration and its concentration with time and this  
depend on four main factors which are absorption, distribution, metabolism and 
excretion, while pharmacodynamic concerned with the response produced in relation to 
drug concentration. So generally drug interactions can be divided into pharmacokinetic 
and pharmacodynamic related interactions (Griffin and D’arcy, 1997). 
 
1.6 Herb-Drug Interaction 
Due to the high attention and use of alternative medicine by the public and lack of 
informations about its contents, there is a high possibility of herb-drug interactions (Izzo 
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and Ernst, 2001). Such interaction between herbs and drugs may occur in aspects of 
pharmacokinetic and pharmacodynamic of drug. Herb-drug interaction can be defined as 
any change either in the pharmacokinetic or pharmacodynamic of the drug which is 
caused by concurrent administration of drug with the herb (Sugiyama et al., 2004). As a 
result of herbal-drug interactions, three possible outcomes can arise which are: 
1. an increase in therapeutic or adverse effects. 
2. a decrease in therapeutic or adverse effects. 
3. a unique response that does not appear when either agent is used alone.  
 
1.6.1    Nature of Herb-Drug Interaction 
 Natural products unlike conventional drugs, have a complex mixture of bioactive 
entities and a complete characterization and determination of these bioactive chemical 
constituents is usually unknown. Additionally, varying growing conditions of the plant, 
seasonality, manufacturing method, the combination of two or more plants in herbal 
products and poor control from Food & Drug Administration (FDA) make the whole 
issue of interactions more complex (Chen et al., 2008). 
 
1.6.1.1    Pharmacokinetic Interactions 
This kind of interaction is concerned with changes in absorption, distribution, 
metabolism and excretion of interacting molecules. Thus any alteration of these 
processes will cause a change in the amount and persistence of drug molecules at 
receptor sites or target tissue. 
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a)    Absorption 
It is the process by which a test compound and its metabolites are transferred from 
the site of administration to the systemic circulation. Intestine is the major site of 
absorption for drugs and herbs after oral administration. Bioavailability of the drug 
given orally depends on absorption process because it reflects the total amount of drug 
and its derived materials inside the body (Tse and Jaffe, 1991). 
 
Several studies showed that herbal medicinal products may affect the absorption of 
other drugs and consequently affect the bioavailability of these drugs inside the body. 
Some herbs may inhibit intestinal CYP3A4 activity, which possess an important role in 
the metabolism of variety of drug leading to increase in their bioavailability, for example 
grape fruit juice inhibit CYP3A4 in the enterocyte of intestine leading to an increase in 
the bioavailability and appearance of side effects of other drugs like Ca-channel 
blockers, HIV protease inhibitors, vinblastine, digoxin, cyclosporine and fexofenadine 
(Pandit, 2006). Some other herbal products may interfere with P-glycoprotein activity, 
which is an important transporter in the intestine responsible for actively expelling 
chemotherapeutic drugs from cells, so it decreases drug intracellular concentration and 
thus drug efficacy; the plant St Johns wort, which is used for depression is an example of 
plant that is found to cause an induction of P-glycoprotein activity leading to a 
significant reduction of serum level for some drugs like digoxin (Hennessy et al., 2002). 
 
Other mechanisms of herbal-drug interactions that may affect the absorption and 
consequently bioavailability of drugs are changes in intestinal motility and changes in 
the pH of the stomach. 
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b)    Distribution 
Human body should not be considered as one compartment of fluid throughout 
which  chemicals  are  distributed,  but  it  is  multi  compartmental   system. The  largest  
compartment is the intracellular fluid, which account for about 65% of total body water. 
The second large compartment is interstitial fluid, which account about 24% of total 
body water, while blood plasma account for about 8%. The synovial fluid, intraocular 
and cerebrospinal fluid account for about 3% of total body water. The other major body 
compartment is fat, which account about 20% of body weight (Gard, 2001). 
 
Xenobiotics (like drugs and herbs) and endogenous compounds are distributed in 
the body between various compartments depending on many factors like: lipid 
solubility, plasma protein binding, blood pH and blood flow to tissues (Gard, 2001). 
Water-soluble drugs have low volume of distribution with tendency to remain in blood, 
while fat-soluble drugs possess a high volume of distribution as they diffuse to many 
tissues and organs. However, effect on distribution due to drug-drug or herb-drug 
interactions usually happened due to displacement of drug from its binding sites like 
plasma proteins leading to increase in the free (active) concentration, but this action 
mainly do not show significant change on drug pharmacokinetic due to simultaneous 
increase in metabolism and elimination (Gregory, 2007).  
 
Cautions of herb-drug interaction on drug distribution are mainly on drugs with high 
plasma protein binding capacity and low margin of safety as warfarin, which showed a 
distribution disturbance when administered with tea or other green leafy vegetables 
(Lambrecht et al., 2000). 
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c) Metabolism 
Liver is the site that is responsible chiefly for the most metabolic reactions, although 
some enzymes and metabolic reactions  occur  in  the  intestine, lung  and  kidney. These       
metabolic reactions are divided into two phases, known as phase I (functionalization 
reactions) and Phase II (conjugation reactions).  
 
Cytochrome P450 system, which comprises more than 50 enzymes are responsible 
for most reactions of Phase I and it is found mainly in the liver and to a lesser extend in 
the lung, kidney, skin and intestine.  
 
      Metabolic interactions are the main causes of herb-drug interactions; hence many 
researches have been done to examine the effect of drug-drug and herb-drug interactions 
on cytochrome P450 enzyme activity. Any alteration in enzyme activity means that 
some interaction happened between two drugs or herb and drug given at the same time. 
Examples of such interactions are: goldenseal (Hydrastis canadensis) causes an 
inhibition of CYP2D6 and CYP3A4/5. Black cohosh (Cimicifuga racemosa) inhibits 
CYP2D6. Kava kava (Piper methysticum) and garlic oil inhibits CYP2E1 (Gurley et al., 
2002; Gurley et al., 2005) and St Johns Wort was found to possess an induction effect on 
CYP3A4 (Dürr et al., 2000; Wang et al., 2001). 
 
d)    Excretion 
Kidneys are regarded as the major organs of excretion and to a lesser extend faeces, 
saliva, sweat, breast milk and lungs as other route of excretion. If a drug is excreted by 
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one pathway, then alteration to that pathway theoretically have a significant influence on 
its excretion. 
 
Drug-drug and herb-drug interactions can affect renal function and consequently 
affect excretion through three main mechanisms which are: 
 changes in urinary pH, which alter renal tubular re-absorption. 
 changes in renal tubular secretion due to alteration of membrane transporter 
proteins activity or competition for active secretion. 
 changes in glomerular filtration due to the effect on cardiac output  (Blower et 
al., 2005). 
 
Urinary pH alteration is easily achieved with herbs and natural substances like high 
protein diet that may cause alkalization of urine leading to increase in excretion of 
weakly basic drugs such as amphetamine (Braun and Cohen, 2007). 
 
1.6.1.2    Pharmacodynamic Interactions 
This type of interaction results when one substance alters the responsiveness or 
sensitivity of tissues to another. Such type of interaction results in synergistic, additive 
or antagonistic drug effects which may be of particular importance when drugs used 
simultaneously have overlapping toxicities. 
 
Some clinicians frequently use synergistic or additive pharmacodynamic 
interactions to improve the clinical outcome, like the combination of antibiotics to 
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eradicate microorganisms or using several antihypertensive drugs to one patient. The 
same way are used for herbal treatment, where combination of herbs are used to 
strengthen the effect on certain ailment, but such pharmacodynamic interaction do not 
always produce desired results due to overlapping adverse effects when drugs and herbs 
are combined together leading to serious adverse effects. For example, using Kava-kava 
(Piper methysticum), which has dopamine receptor antagonist activity, theoretically can 
interact with dopamine agonists (e.g. L-dopa) opposing their effect (Meseguer et al., 
2002). Another example is that ginger, ginkgo and garlic may potentiate the 
anticoagulant action of warfarin (Barnes et al., 2003). 
 
1.6.1.3    Physicochemical Interactions 
This type of interactions occurs when two substances are in contact and are 
physically or chemically incompatible. Such interactions may affect the rate and extend 
of absorption of one or both drugs. Herbs, which contain significant amount of tannins is 
a potential candidate of physicochemical interactions because it form precipitate with 
proteins, polysaccharides, glycosides, nitrogen bases and some alkaloids (Mills, 1991). 
Tannins containing herbs such as Agrimony eupatorium and Arctostaphylus uva-ursi can 
also form complexes with metal ions like iron, thus inhibiting their absorption (Glahn et 
al., 2002).  
 
Some physicochemical interactions may enhance the bioavailability and effect of 
interacting compound. For example, the solubility of hypericin and pseudohypericin 
may increase 60 % in the presence of flavonoid procyanidin (Butterweck et al., 1998). 
Saponins containing plants like Astragalus membranaceus and Bupleurum falcatum, 
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may increase absorption, oral bioavailability and dermal penetration of poorly lipid 
soluble compounds due to micellisation process (Braun and Cohen, 2007).  
 
1.7 Phyllanthus Genus 
Phyllanthus is a very large genus, as more than 550 species have been discovered so 
far (Unander et al., 1995). P. niruri, P. amarus and P. urinaria are the main species 
which have been used in herbal medicine. These species resemble each other in physical 
characteristics with small differences, for example, P. urinaria has a large leaves, its 
fruit is wart like (Cao, 2009) and its flowers are yellow in color (Bharatiya, 1992), while 
P. amarus and niruri have small oblong leaves, its fruits are small glabose capsules and 
the flowers are green to white color (Panda, 2000).   
 
1.8  Literature Review of P. niruri Linn. 
 
1.8.1 Botanical Aspects of P. niruri 
 
Kingdom                               Plantae 
Division                                 Magnoliophyta 
Class Magnoliopsida 
Order Euphorbiales 
Family Euphorbiaceae 
Genus Phyllanthus 
Species niruri 
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 P. niruri is found in most tropical and sub-tropical regions of the world. It is an 
annual herb that grows up to 30-60 cm in high, the stem is often branched at the base 
and leaves are numerous small and oblong in shape. The flowers are minute green in 
color that occurs in groups at the axillary position of leaves, the male flower 1-3 female 
flowers solitary. The fruit has a small surface and glabose capsule with about 2.5 mm in 
diameter (Panda, 2000). Each country that use P. niruri has a local name for it, as shown 
in Table 1.4. 
 
Table 1.4: The Local Names of P. niruri in Various Countries: 
Country Traditional name of P. niruri 
Malaysia Dukong anak 
India Bhoomi amalaki 
Peru Chancapiedra 
Haiti Derriere-dos 
Sudan Elrageig 
Brazil Phyllanto 
Thailand Ya-tai-bai 
Philippines Yerba de san pablo 
                                                                                                                          (Ross, 2003) 
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Leaves of P. niruri Linn. 
 
Figure 1.1: Picture of P. niruri 
 
 
 
